What's Happening?
The U.S. Food and Drug Administration (FDA) has granted approval to BeOne Medicines' Beqalzi and Taiho Oncology's Inqovi for the treatment of specific blood cancers. Beqalzi, a BCL2 inhibitor, received accelerated approval as a third-line or later therapy
for mantle cell lymphoma (MCL), a type of non-Hodgkin lymphoma. This marks the first FDA approval for Beqalzi, following its clearance by China's NMPA. The drug is noted for its greater potency and selectivity, potentially improving efficacy and tolerability compared to existing BCL2 inhibitors. Meanwhile, Taiho's Inqovi, a combination of decitabine and cedazuridine, has been approved for use with Venclexta as an all-oral therapy for newly diagnosed acute myeloid leukemia (AML) in patients aged 75 and over who cannot tolerate intensive chemotherapy. This approval is based on the phase 2 ASCERTAIN-V study, which showed a complete remission rate of 41.6%.
Why It's Important?
These FDA approvals are significant as they introduce new treatment options for patients with specific types of blood cancers, potentially improving outcomes and quality of life. Beqalzi's approval for MCL offers a new therapeutic option in a niche market, potentially reducing competition and allowing BeOne to establish a foothold in the treatment of non-Hodgkin lymphoma. For Taiho, the approval of Inqovi provides an alternative to more invasive treatments for elderly AML patients, addressing a critical need for less intensive therapeutic options. These developments could influence the competitive landscape in the oncology sector, particularly in the market for BCL2 inhibitors and AML treatments.
What's Next?
BeOne plans to expand the use of Beqalzi into other indications, including chronic lymphocytic leukemia and acute myeloid leukemia, where it will face competition from existing drugs like Venclexta. The next data readout for Beqalzi is expected from the CELESTIAL-TNCLL trial, which will compare its efficacy in combination with Brukinsa against Venclexta and Gazyva in untreated chronic lymphocytic leukemia. For Taiho, the focus will likely be on monitoring the real-world effectiveness of Inqovi in combination with Venclexta and exploring further applications of this regimen in other patient populations.
